Concurrent Session III - HOT TOPICS IN GASTROENTEROLOGY
Moderators: Norelle Reilly, MD, Columbia University Medical Center and James Heubi, MD, Cincinnati Children's Hospital Medical Center

Emerging therapies in NAFLD: Hope or hype?
Stavra Xanthakos, MD, Cincinnati Children's Hospital Medical Center
Objectives:
  • Review potential therapeutic targets for NAFLD
  • Summarize completed and ongoing clinical trials of pharmacotherapy and nutraceuticals for NAFLD
  • Understand challenges to developing effective pharmacotherapies for NAFLD
Stavra Xanthakos
(Adobe PDF File)
Polypharmacy in GI: Are we treating the parent or the patient?
Samuel Nurko, MD, Boston Children's Hospital
Objectives:
  • Review the different treatments available for functional Gi diseases
  • Understand why multiple pharmacological approaches may be needed
  • Review the main known group interactions
  • Explore if it is possible to better tailor therapy
Samuel Nurko
(Adobe PDF File)
449  PAI-1 AS AN EPITHELIAL MARKER OF DISEASE SEVERITY IN PEDIATRIC EOSINOPHILIC ESOPHAGITIS. Prerana Williamson1,2,3, Ranjan Dohil1,2,3, Maheen Hassan1,2,3, Armen Gharibans3,4,5, Jacqueline Barsamian3, Lucas Dohil1,8, Robert Newbury3,6, Hayat Mousa1,2,3, Seema Aceves3,7,8. 1Department of Pediatrics, University of California San Diego, San Diego, CA, USA; 2Division of Pediatric Gastroenterology, University of California San Diego, San Diego, CA, USA; 3Rady Children's Hospital, San Diego, CA, USA; 4Department of Surgery, University of Auckland, Auckland, New Zealand; 5Auckland Bioengineering Institute, University of Auckland, Auckland, New Zealand; 6Department of Pathology, University of California San Diego, San Diego, CA, USA; 7Department of Medicine and Pediatrics, University of California San Diego, San Diego, CA, USA; 8Division of Allergy and Immunology, University of California San Diego, San Diego, CA, USA
Prerana Williamson
(Adobe PDF File)
To AGRE(o)E or DIS-Agree: Eosinophilic esophagitis management from the real-world perspective
Joshua Brian Wechsler, MD, Ann & Robert H. Lurie Children's Hospital of Chicago
Objectives:
  • Identify complex cases of diagnosis and treatment that emphasize the need for new guidelines on PPIs
  • Discuss PPI response as a treatment-subtype of Eosinophilic Esophagitis
  • Define realistic practice standards for diagnosis and management with regards to PPI therapy
Joshua Brian Wechsler
(Adobe PDF File)